GemOx regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:GEM-OX Regimen; Gemcitabine-Oxaliplatin Regimen; GEMOX Regimen
Overview
Overview
GemOx regimen refers to a regimen consisting of gemcitabine and oxaliplatin used for the treatment of biliary adenocarcinoma, pancreatic cancer, hepatocellular cancer[1] and testicular cancer[2]. This regimen is currently being studied in a variety of other cancers.
Regimen
Regimen
GemGemcitabine
OxOxaliplatin
Indications
Indications
References
References
- ↑ 1.0 1.1 Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L; et al. (2014). “Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies”. Invest New Drugs. 32 (5): 1028–35. doi:10.1007/s10637-014-0100-y. PMID 24748335.
- ↑ 2.0 2.1 Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M; et al. (2004). “Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study”. Ann Oncol. 15 (3): 493–7. PMID 14998855.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH